文献速递流行病学与生物统计临床试验与 GCP

成人超重与肥胖的药物治疗:随机对照试验的系统综述与网络Meta分析

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
PubMed 文献 · Lancet · 2024-01-01

该系统综述与网络Meta分析检索截至2021年3月23日的PubMed、Embase和Cochrane Library,纳入132项随机对照试验共48209名超重或肥胖成人,评估减重药物的获益与危害。与单纯生活方式干预相比,所有药物均降低体重;芬特明-托吡酯和GLP-1受体激动剂减重效果最好,其中司美格鲁肽可能最有效。

要点

  • 芬特明-托吡酯减重效果最佳,≥5%体重下降的OR为8.02(95%CI 5.24-12.27)。
  • GLP-1受体激动剂次之,≥5%体重下降的OR为6.33(95%CI 5.00-8.00)。
  • 纳曲酮-安非他酮、芬特明-托吡酯、GLP-1受体激动剂和奥利司他与因不良事件停药增加相关。

核心结论

  • 在超重和肥胖成人中,芬特明-托吡酯和GLP-1受体激动剂是减重效果最好的药物;在GLP-1受体激动剂中,司美格鲁肽可能最有效。

研究设计与样本

  • 系统综述与网络Meta分析,检索PubMed、Embase和Cochrane Library(CENTRAL)自建库至2021年3月23日,纳入132项随机对照试验共48209名超重或肥胖成人。
  • 采用频率学派随机效应网络Meta分析,应用GRADE框架评级证据确定性并计算绝对效应。
  • 研究注册于PROSPERO,注册号CRD 42021245678。

主要发现

  • 与单纯生活方式干预相比,所有药物均降低体重。
  • 高至中等确定性证据表明芬特明-托吡酯减重效果最佳,≥5%体重下降的OR为8.02(95%CI 5.24-12.27),体重变化百分比的MD为-7.98(95%CI -9.27至-6.69)。
  • GLP-1受体激动剂次之,≥5%体重下降的OR为6.33(95%CI 5.00-8.00),体重变化百分比的MD为-5.79(95%CI -6.34至-5.25)。
  • 纳曲酮-安非他酮(OR 2.69,95%CI 2.10-3.44)、芬特明-托吡酯(OR 2.40,95%CI 1.68-3.44)、GLP-1受体激动剂(OR 2.22,95%CI 1.74-2.84)和奥利司他(OR 1.71,95%CI 1.42-2.05)与因不良事件停药增加相关。
  • 事后分析中,司美格鲁肽在≥5%体重下降(OR 9.82,95%CI 7.09-13.61)和体重变化百分比(MD -11.40,95%CI -12.51至-10.29)方面显示出比其他药物更大的获益,不良事件风险与其他药物相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmacotherapy provides an option for adults with overweight and obesity to reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for the benefits and harms of weight-lowering drugs. METHODS: This systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled trials of weight-lowering drugs in adults with overweight and obesity. We performed frequentist random-effect network meta-analyses to summarise the evidence and applied the Grading of Recommendations Assessment, Development, and Evaluation frameworks to rate the certainty of evidence, calculate the absolute effects, categorise interventions, and present the findings. The study was registered with PROSPERO, CRD 42021245678. FINDINGS: 14 605 citations were identified by our search, of which 132 eligible trials enrolled 48 209 participants. All drugs lowered bodyweight compared with lifestyle modification alone; all subsequent numbers refer to comparisons with lifestyle modification. High to moderate certainty evidence established phentermine-topiramate as the most effective in lowering weight (odds ratio [OR] of ≥5% weight reduction 8·02, 95% CI 5·24 to 12·27; mean difference [MD] of percentage bodyweight change -7·98, 95% CI -9·27 to -6·69) followed by GLP-1 receptor agonists (OR 6·33, 95% CI 5·00 to 8·00; MD -5·79, 95% CI -6·34 to -5·25). Naltrexone-bupropion (OR 2·69, 95% CI 2·10 to 3·44), phentermine-topiramate (2·40, 1·68 to 3·44), GLP-1 receptor agonists (2·22, 1·74 to 2·84), and orlistat (1·71, 1·42 to 2·05) were associated with increased adverse events leading to drug discontinuation. In a post-hoc analysis, semaglutide, a GLP-1 receptor agonist, showed substantially larger benefits than other drugs with a similar risk of adverse events as other drugs for both likelihood of weight loss of 5% or more (OR 9·82, 95% CI 7·09 to 13·61) and percentage bodyweight change (MD -11·40, 95% CI -12·51 to -10·29). INTERPRETATION: In adults with overweight and obesity, phentermine-topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective. FUNDING: 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024. PMID: 38582569. doi:10.1016/S0140-6736(24)00351-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。